To identify the breast cancer patients that will benefit from MEK1 targeting, it will be important to determine the various mechanisms regulating BimEL expression and function in T-47D cells and in other breast cancer cell models that express low levels of Bim. The gene discussed is MAP2K1; the disease is breast carcinoma.